孟鲁司特与噩梦:基于VigiBase数据的进一步特征分析
该研究对VigiBase中截至2020年5月3日报告的孟鲁司特相关噩梦进行临床审阅,共纳入1118份报告,发现约半数被归为严重报告,三分之二涉及儿童,以5–10岁最多;多数病例停药后噩梦消失,但部分患者需较长时间才缓解。
要点
- 孟鲁司特相关噩梦报告约半数被归为严重,三分之二涉及儿童。
- 多数病例停药后噩梦消失,但部分患者缓解需较长时间。
- 应持续监测用药期间获益-风险,并向患者与医务人员提示该反应。
核心结论
- 孟鲁司特相关噩梦报告描述了其性质与潜在严重性,对患者和医务人员具有重要参考价值,有助于减少药物所致伤害。
- 研究强调上市后报告对进一步刻画已知药物不良反应的价值。
- 患者服用孟鲁司特期间应持续监测获益-风险平衡。
研究设计与样本
- 对VigiBase(世界卫生组织全球疑似药物不良反应数据库,由乌普萨拉监测中心开发维护)中截至2020年5月3日的孟鲁司特相关噩梦报告进行临床审阅。
主要发现
- VigiBase中共有1118份孟鲁司特相关噩梦报告,提供了噩梦的具体描述及对日常生活影响的信息,许多病例描述了严重影响。
- 约半数报告被归为严重报告。
- 三分之二报告涉及儿童,其中占比最大的年龄组为5–10岁儿童。
- 多数病例停药后噩梦消失,但部分患者需较长时间噩梦才停止。
临床怎么用
- 临床应认识到孟鲁司特相关噩梦可能较严重并影响日常生活,尤其关注儿童用药者。
- 向患者及照护者提示该不良反应,出现噩梦时评估停药等处理,并注意部分患者缓解需较长时间。
- 用药期间持续关注获益-风险平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Montelukast is a medicine indicated for use in asthma. Psychiatric disorders including nightmares have not been described in clinical trials but during recent years have been included in the product information as having been reported post-marketing, without further description of the events. Previous descriptions in the scientific literature were based on limited numbers of reports or lacked detailed case information. OBJECTIVE: The study aim was to further characterise post-marketing adverse drug reactions for nightmares, suspected to be induced by montelukast, to facilitate safer use of the medicine by providing additional information to patients and healthcare professionals. METHODS: We clinically reviewed reports of nightmares with montelukast present in VigiBase, World Health Organization's global database of suspected adverse reactions to medicinal products, developed and maintained by the Uppsala Monitoring Centre, until 3 May, 2020. RESULTS: There were 1118 reports of nightmares with montelukast in VigiBase, which provided valuable descriptions of the nightmares as well as information about the impact on the daily lives, with many cases describing a severe impact of the nightmares. About half of the reports were classified as serious. Two thirds concerned children, with the largest age group represented being children aged 5-10 years. In most cases, the nightmares disappeared upon discontinuation of the drug but for some patients it took a long time until the nightmares ceased. CONCLUSIONS: The nature and potential severity of this adverse drug reaction, as described in these reports, present important knowledge for patients and healthcare providers that could help reduce drug-induced harm. This study highlights the value of post-marketing reports for further characterisation of known adverse drug reactions. The benefit-risk balance should be continuously monitored while patients are taking montelukast.
引用
- Watson S, Kaminsky E, Taavola H, et al. Montelukast and Nightmares: Further Characterisation Using Data from VigiBase. Drug Saf. 2022. PMID: 35650509. doi:10.1007/s40264-022-01183-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。